(cid:258)(cid:396)(cid:272)(cid:346)(cid:349)(cid:448)(cid:286)(cid:856)(cid:381)(cid:396)(cid:336)(cid:3)
`
`(cid:36)(cid:41)(cid:41)(cid:44)(cid:39)(cid:36)(cid:57)(cid:44)(cid:55)(cid:3)(cid:50)(cid:41)(cid:3)(cid:49)(cid:36)(cid:55)(cid:43)(cid:36)(cid:49)(cid:44)(cid:40)(cid:47)(cid:3)(cid:40)(cid:3)(cid:41)(cid:53)(cid:36)(cid:49)(cid:46)(cid:16)(cid:58)(cid:43)(cid:44)(cid:55)(cid:40)(cid:3)
`
`1.
`
`I am a Records Request Processor at the Internet Archive, located in San Francisco,
`California. I make this declaration of my own personal knowledge.
`
`2. The Internet Archive is a website that provides access to a digital library of Internet
`sites and other cultural artifacts in digital form. Like a paper library, we provide
`free access to researchers, historians, scholars, and the general public. The Internet
`Archive has partnered with and receives support from various institutions,
`including the Library of Congress.
`
`3. The Internet Archive has created a service known as the Wayback Machine. The
`Wayback Machine makes it possible to browse more than 450 billion pages stored
`in the Internet Archive's web archive. Visitors to the Wayback Machine can search
`archives by URL (i.e., a website address). If archived records for a URL are
`available, the visitor will be presented with a display of available dates. The visitor
`may select one of those dates, and begin browsing an archived version of the Web.
`Links on archived files in the Wayback Machine point to other archived files
`(whether HTML pages or other file types), if any are found for the URL indicated
`by a given link. For instance, the Wayback Machine is designed such that when a
`visitor clicks on a hyperlink on an archived page that points to another URL, the
`(cid:89)(cid:76)(cid:86)(cid:76)(cid:87)(cid:82)(cid:85)(cid:3)(cid:90)(cid:76)(cid:79)(cid:79)(cid:3)(cid:69)(cid:72)(cid:3)(cid:86)(cid:72)(cid:85)(cid:89)(cid:72)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:85)(cid:70)(cid:75)(cid:76)(cid:89)(cid:72)(cid:71)(cid:3)(cid:73)(cid:76)(cid:79)(cid:72)(cid:3)(cid:73)(cid:82)(cid:88)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:75)(cid:92)(cid:83)(cid:72)(cid:85)(cid:79)(cid:76)(cid:81)(cid:78)(cid:182)(cid:86)(cid:3)(cid:56)(cid:53)(cid:47)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)
`closest available date to the initial file containing the hyperlink.
`
`4. The archived data made viewable and browsable by the Wayback Machine is
`obtained by use of web archiving software that automatically stores copies of files
`available via the Internet, each file preserved as it existed at a particular point in
`time.
`
`5. The Internet Archive assigns a URL on its site to the archived files in the format
`http://web.archive.org/web/[Year in yyyy][Month in mm][Day in dd][Time code in
`(cid:75)(cid:75)(cid:29)(cid:80)(cid:80)(cid:29)(cid:86)(cid:86)(cid:64)(cid:18)(cid:62)(cid:36)(cid:85)(cid:70)(cid:75)(cid:76)(cid:89)(cid:72)(cid:71)(cid:3)(cid:56)(cid:53)(cid:47)(cid:64)(cid:3)(cid:68)(cid:78)(cid:68)(cid:3)(cid:68)(cid:81)(cid:3)(cid:179)(cid:72)(cid:91)(cid:87)(cid:72)(cid:81)(cid:71)(cid:72)(cid:71)(cid:3)(cid:56)(cid:53)(cid:47)(cid:180)(cid:17) Thus, the extended URL
`http://web.archive.org/web/19970126045828/http://www.archive.org/ would be the
`URL for the record of the Internet Archive home page HTML file
`(http://www.archive.org/) archived on January 26, 1997 at 4:58 a.m. and 28
`seconds (1997/01/26 at 04:58:28). The date indicated by an extended URL applies
`to a preserved instance of a file for a given URL, but not necessarily to any other
`files linked therein. Thus, in the case of a page constituted by a primary HTML file
`and other separate files (e.g., files with images, audio, multimedia, design
`elements, or other embedded content) linked within that primary HTML file, the
`primary HTML file and the other files will each have their own respective extended
`URLs and may not have been archived on the same dates.
`
`6. Attached hereto as Exhibit A are true and accurate copies of screenshots of the
`Internet Archive's records of the archived files for the URLs and the dates specified
`in the attached coversheet of each printout.
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0001
`
`

`

`(cid:258)(cid:396)(cid:272)(cid:346)(cid:349)(cid:448)(cid:286)(cid:856)(cid:381)(cid:396)(cid:336)(cid:3)
`
`7.
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`
`
`
`04/01/2022
`DATE: ________________________
`
`
`________________________
`Nathaniel E Frank-White
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0002
`
`

`

`
`
`
`
`
`EXHIBIT A
`EXHIBIT A
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0003
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0003
`
`

`

`(cid:346)(cid:410)(cid:410)(cid:393)(cid:400)(cid:855)(cid:876)(cid:876)(cid:449)(cid:286)(cid:271)(cid:856)(cid:258)(cid:396)(cid:272)(cid:346)(cid:349)(cid:448)(cid:286)(cid:856)(cid:381)(cid:396)(cid:336)(cid:876)(cid:449)(cid:286)(cid:271)(cid:876)(cid:1006)(cid:1004)(cid:1004)(cid:1011)(cid:1004)(cid:1011)(cid:1004)(cid:1013)(cid:1005)(cid:1010)(cid:1005)(cid:1006)(cid:1006)(cid:1010)(cid:876)(cid:346)(cid:410)(cid:410)(cid:393)(cid:855)(cid:876)(cid:349)(cid:374)(cid:448)(cid:286)(cid:400)(cid:410)(cid:381)(cid:396)(cid:856)(cid:393)(cid:346)(cid:258)(cid:396)(cid:373)(cid:349)(cid:381)(cid:374)(cid:856)(cid:272)(cid:381)(cid:373)(cid:876)(cid:393)(cid:346)(cid:381)(cid:286)(cid:374)(cid:349)(cid:454)(cid:856)(cid:460)(cid:346)(cid:410)(cid:373)(cid:367)(cid:845)(cid:272)(cid:1089)(cid:1005)(cid:1008)(cid:1006)(cid:1004)(cid:1008)(cid:1009)
`(cid:920)(cid:393)(cid:1089)(cid:349)(cid:396)(cid:381)(cid:367)(cid:882)(cid:374)(cid:286)(cid:449)(cid:400)(cid:4)(cid:396)(cid:410)(cid:349)(cid:272)(cid:367)(cid:286)(cid:920)(cid:47)(cid:24)(cid:1089)(cid:1005)(cid:1004)(cid:1005)(cid:1004)(cid:1007)(cid:1011)(cid:1010)(cid:920)(cid:346)(cid:349)(cid:336)(cid:346)(cid:367)(cid:349)(cid:336)(cid:346)(cid:410)(cid:1089)(cid:3)
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0004
`
`

`

`CompanyManagement
`Board ofDirectors
`Corporate Governance
`Stock Information
`Corporate Presentations
`> News Releases
`Email Alerts
`Event Calendar
`Analyst Coverage
`SECFilings
`Investor FAQs
`Webcasts and Podcasts
`IR Contacts
`Media Center
`
`Portcy » News Release
`
`Pa)
`Our Products
`Healthcare Professionals
`
`Business Development
`
`& Print Version
`
`<< Back
`Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine
`Bioavailability Data from First Oral Demethylating Agent in Clinical Trials
`Presented at the American Society of Clinical Oncology 43rd Annual Meeting
`CHICAGO, June 2 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM)
`today reported data from a pilot study that demonstrated the bioavailability of the
`Company's oral dosage formulation of Azacitidine. These data were presented at the
`43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in
`Chicago. (June 1-5, 2007). Pharmion's epigenetic anti-cancer products, which
`include Vidaza(R) (azacitidine for injection), MCGD0O103 and oral Azacitidine, are
`being investigated in the treatment of hematologic malignancies and solid tumors
`and are the subject of poster and oral presentations at the Meeting.
`An oral dosage formulation of Azacitidine would provide a more desirable and
`convenient route of administration for patients and clinical staff and eliminate
`injection-site reactions. In addition, it would enable the evaluation of a low-dose
`regimen that could maximize demethylation and gene re-expression, as well as the
`evaluation of long-term or maintenance therapy.
`The study was designed to assess thesafety, tolerability, and pharmacokinetics of
`escalating single doses of orally administered Azacitidine in patients with
`Myelodysplastic Syndromes (MDS), acute myeloid leukemia (AML) or othersolid
`tumors. A total of four patients were enrolled and received study drug. One patient
`received a 60 mg dose andthree patients received a single 80 mg dose. In each
`case, Azacitidine was well-tolerated and quantifiable in plasma. Following an 80mg
`dose the bioavailability of the oral formulation of Azacitidine was 18 percentrelative
`to subcutaneous (SC) administered Vidaza. Having established that acceptable
`plasma concentrations of azacitidine can be achieved with single oral dosing, this
`pilot study has concluded. A multi-dose escalating study of oral azacitidine is now
`underway.
`"Oral azacitidine represents an extremely exciting opportunity," said Dr. Guillermo
`Garcia-Manero, Associate Professor of Medicine and Chief, Section of Myelodysplastic
`Syndromes, Department of Leukemia, M.D. Anderson Cancer Center. "The potential
`for a chronic oral demethylating agent will not only apply to MDS but to many other
`tumor types as well. This is a very important step forward for epigenetic therapies."
`Data Presented Saturday, June 2
`Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC)
`inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk
`Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) - G.
`Garcia-Manero, MD, MD Anderson Cancer Center; Abstract #7062; June 2, 2007;
`8:00-12:00 pm; McCormick Convention Center, S Hall A2
`The combination of 5-azacytidine and valproic acid is safe and active in advanced
`solid tumors - A.O. Soriano, MD Anderson Cancer Center; Abstract #3547; June 2,
`2007; 2:00-6:00pm; McCormick Place Convention Center, S102a
`Contact details
`Breanna Burkart or Anna Sussman
`Directors, Investor Relations and Corporate Communications
`Pharmion Corporation
`Tel: +1 720 564 9144 or +1 720 564 9143
`
`Tara May
`On-site media contact
`Tel: +1 303 646 7832
`About Vidaza
`
`Vidaza wasthefirst drug approved for the treatmentof all five subtypes of
`myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory
`anemia with ringed sideroblasts (RARS)(if accompanied by neutropenia or
`thrombocytopenia or requiring transfusions), refractory anemia with excess blasts
`(RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and
`chronic myelomonocytic leukemia (CMMoL).
`Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of
`DNAand direct cytotoxicity on abnormal hematopoietic cells in the bone marrow.
`The concentration of azacitidine required for maximum inhibition of DNA methylation
`in vitro does not cause major suppression of DNA synthesis. Hypomethylation may
`restore normal function to genes that are critical for differentiation and proliferation.
`The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including
`cancercells that are no longer responsive to normal growth control mechanisms.
`Non- proliferating cells are relatively insensitive to Vidaza.
`Important Safety Information
`Vidaza is contraindicated in patients with a known hypersensitivity to azacitidine or
`mannitol and in patients with advanced malignant hepatic tumors. In clinical studies,
`the most commonly occurring adverse reactions were nausea (70.5%), anemia
`(69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%),
`leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema
`(35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%).
`Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile
`neutropenia(16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated
`fatigue (12.7%) and malaise (10.9%). Because treatment with Vidaza is associated
`wa elea ee ee ee ee te Le te te
`with neutropenia and thrombocytopenia, complete blood counts should be
`
`
`
`INTERNET ARCHIVE
`Go
`
` http://investor.pharmion.com/phoenix.zhtml?c=142045&pz=irol-newsArticle&ID=1010376&highlight=
`
`
`
`+capture
`WWAUD9CHMACHINE
`09 Jul 2007
`
`Hee
`ho
`'Y Aboutthis capture
`
`
`
`potex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0005
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0005
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0005
`
`

`

`Penornned as Neeued LO MOMILor fespornse amd LOXICILy, DUL al a@ IMINNnNUMm, prior Lo
`each dosing cycle. Because azacitidine is potentially hepatotoxic in patients with
`severe pre- existing hepatic impairment, caution is needed in patients with liver
`disease. In addition, azacitidine and its metabolites are substantially excreted by the
`kidneys and therisk of toxic reactions to this drug may be greater in patients with
`impaired renal function. Because elderly patients are morelikely to have decreased
`renal function, it may be useful to monitor renal function. Vidaza may causefetal
`harm. While receiving treatment with Vidaza, womenof childbearing potential
`should avoid becoming pregnant, and men should avoid fathering a child. In
`addition, womentreated with Vidaza should not nurse.
`About MDS
`
`The highest prevalence of MDSis in patients over 60 years of age. According to the
`American Cancer Society and the Aplastic Anemia and MDSInternational
`Foundation, there are approximately 10,000-30,000 new cases of MDSin the United
`States each year. Survival ranges from six months to many yearsfor the different
`subtypes of MDS.
`About Epigenetics
`DNA methylation and histone deacetylation are two of the more studied epigenetic
`regulators of gene expression. Epigenetics refers to changes in the regulation of
`gene expression. Epigenetic changes can silence gene expression and, unlike DNA
`mutations, may be reversed by targeting the enzymesinvolved. The silencing of key
`cell cycle control genes and tumor suppressor genes through these two mechanisms
`of epigenetic regulation have been demonstratedin vitro and in vivo in
`hematological malignancies and in solid tumors. Vidaza has been shownto reverse
`the effects of DNA hypermethylation with subsequent gene re-expression and
`likewise MGCD0103 has been shown,in vivo, to reverse the effects of inappropriate
`deacetylation resulting in gene expression reactivation. The epigenetic approach to
`cancer therapy is that rather than using molecules that kill both normal and tumor
`cells, the silenced genes are reactivated through targeted epigenetic therapy, re-
`establishing the cancercell's natural mechanisms to control abnormal growth.
`About Pharmion
`
`http://www.pharmion.com /
`
`co:
`ST:
`IN:
`SU:
`
`Pharmion Corporation; 43rd Annual Meeting of the American Society of
`Clinical Oncology
`Illinois
`HEA MTC BIO
`TRI TDS
`
`AP
`-- CLSA@@8 --
`3536 06/02/2007 13:00 EDT http://www.prnewswire.com
`
`
`
`
`Pharmion is a biopharmaceutical company focused on acquiring, developing and
`commercializing innovative products for the treatment of hematology and oncology
`patients in the U.S., Europe and additional international markets. Pharmion has a
`numberof products on the market including the world's first approved epigenetic
`drug, Vidaza(R), a DNA demethylating agent. For additional information about
`Pharmion,please visit the company's website at www.pharmion.com.
`Safe Harbor Statement underthe Private Securities Litigation Reform Act of 1995:
`This release contains forward-looking statements, including summary statements
`relating to interim or preliminary results of clinical trials involving oral azacitidine.
`Such statements are based on current expectations and involve a number of known
`and unknownrisks and uncertainties that could cause the final results to differ
`significantly from the results summarized by such statements. Some oftheclinical
`trials described in this release are being conducted by independent investigators and
`Pharmion does not control and cannot predict the final results of those trials. Top
`line or preliminary results may not be confirmed uponfull analysis of the detailed
`results of a trial and additional information relating to the safety, efficacy or
`tolerability of oral azacitidine may be discovered upon further analysis ofclinical trial
`data and upon review and analysis of data from otherclinical trials. Additional risks
`and uncertainties relating to Pharmion and its business can be foundin the "Risk
`Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly
`period ended March 31, 2007, its Annual Report on Form 10-K for the year ended
`December 31, 2006 and in Pharmion's otherfilings with the U.S. Securities and
`Exchange Commission. Forward- looking statements speak only as of the date on
`which they are made, and Pharmion undertakes no obligation to update publicly or
`revise any forward- looking statement, whether as a result of new information,
`future developments or otherwise. Pharmionalso disclaims any duty to comment
`upon or correct information that may be contained in reports published by the
`investment community.
`SOURCE Pharmion Corporation
`06/02/2007
`-@-
`/CONTACT: Breanna Burkart, or Anna Sussman, Directors, Investor Relations
`and Corporate Communications, of Pharmion Corporation, +1-720-564-9144 or +1-
`720-564-9143; or Tara May of Pharmion Corporation, On-site media contact, +1-
`303-646-7832/
`/Web site:
`(PHRM)
`
`About Pharmion | Our Products | Healthcare Professionals
`Business Development
`| Investor Relations | Media Center | Careers
`© Pharmion Corporation. All rights reserved. Terms of Use and Privacy
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0006
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0006
`
`

`

`(cid:45)(cid:56)(cid:53)(cid:36)(cid:55)
`
`(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:18)(cid:9)(cid:41)(cid:39)(cid:39)(cid:41)(cid:40)(cid:48)(cid:32)(cid:28)(cid:38)(cid:45)(cid:35)(cid:41)(cid:33)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`TEXAS
`
`(cid:9)(cid:36)(cid:45)(cid:50)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:9)(cid:41)(cid:46)(cid:40)(cid:45)(cid:50)(cid:1)(cid:3)(cid:3)(cid:3)(cid:41)(cid:33)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`Travis
`
`(cid:12)(cid:3)
`(cid:12)(cid:3)(cid:3)(cid:3)
`(cid:12)(cid:3)
`
`(cid:50)(cid:81)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:15)(cid:3)(cid:69)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:3)(cid:80)(cid:72)(cid:15)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:3)(cid:15)(cid:3)
`LaJonae Jonevie Hosang
`04/01/2022
`(cid:39)(cid:68)(cid:87)(cid:72)
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:49)(cid:68)(cid:80)(cid:72)
`(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:74)(cid:82)(cid:76)(cid:81)(cid:74)(cid:3)(cid:76)(cid:81)(cid:86)(cid:87)(cid:85)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87) (cid:90)(cid:68)(cid:86) (cid:86)(cid:88)(cid:69)(cid:86)(cid:70)(cid:85)(cid:76)(cid:69)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:90)(cid:82)(cid:85)(cid:81)(cid:3)(cid:11)(cid:82)(cid:85)(cid:3)(cid:68)(cid:73)(cid:73)(cid:76)(cid:85)(cid:80)(cid:72)(cid:71)(cid:12) (cid:69)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72) (cid:80)(cid:72)(cid:3)(cid:69)(cid:92)(cid:29)
`
`(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:17)
`Nathaniel E Frank-White
`(cid:49)(cid:68)(cid:80)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:36)(cid:73)(cid:73)(cid:76)(cid:68)(cid:81)(cid:87)(cid:11)(cid:86)(cid:12)
`
`(cid:137) (cid:51)(cid:32)(cid:43)(cid:44)(cid:41)(cid:40)(cid:28)(cid:38)(cid:38)(cid:50) (cid:37)(cid:40)(cid:41)(cid:48)(cid:40)(cid:1)(cid:45)(cid:41)(cid:1)(cid:39)(cid:32)(cid:1) (cid:16)(cid:16)(cid:3)(cid:50)(cid:53)(cid:3)(cid:16)(cid:16)
`
`(cid:137) (cid:51)(cid:43)(cid:41)(cid:47)(cid:32)(cid:31)(cid:1)(cid:45)(cid:41)(cid:1)(cid:39)(cid:32)(cid:1)(cid:41)(cid:40)(cid:1)(cid:45)(cid:35)(cid:32)(cid:1)(cid:29)(cid:28)(cid:44)(cid:36)(cid:44) (cid:41)(cid:33) (cid:87)(cid:75)(cid:72)(cid:3)(cid:82)(cid:68)(cid:87)(cid:75)(cid:3)(cid:82)(cid:73)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:3)(cid:16)(cid:16)(cid:3)(cid:50)(cid:53)(cid:3)(cid:16)(cid:16)
`(cid:8)(cid:13)(cid:23)(cid:17)(cid:3)(cid:82)(cid:73)(cid:3)(cid:38)(cid:85)(cid:72)(cid:71)(cid:76)(cid:69)(cid:79)(cid:72)(cid:3)(cid:58)(cid:76)(cid:87)(cid:81)(cid:72)(cid:86)(cid:86)
`(cid:137) (cid:51)(cid:85)(cid:82)(cid:89)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:69)(cid:68)(cid:86)(cid:76)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:72)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:70)(cid:72)(cid:29)(cid:3)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`driver_license
`(cid:137)
`(cid:55)(cid:92)(cid:83)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:44)(cid:39)(cid:3)(cid:51)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:72)(cid:71)
`
`Notarized online using audio-video communication
`
`Notary Public, State of Texas
`
`(cid:24)(cid:14)(cid:22)(cid:17)(cid:11)(cid:21)(cid:21) (cid:39)(cid:50)(cid:1)(cid:35)(cid:28)(cid:40)(cid:31)(cid:1)(cid:28)(cid:40)(cid:31)(cid:1)(cid:41)(cid:33)(cid:33)(cid:36)(cid:30)(cid:36)(cid:28)(cid:38)(cid:1)(cid:44)(cid:32)(cid:28)(cid:38)(cid:5)
`
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:51)(cid:88)(cid:69)(cid:79)(cid:76)(cid:70)(cid:3)(cid:21)(cid:36)(cid:34)(cid:40)(cid:28)(cid:45)(cid:46)(cid:43)(cid:32)(cid:7) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`
`(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`
`(cid:66)(cid:66)
`
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:49)(cid:68)(cid:80)(cid:72)(cid:29)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`LaJonae Jonevie Hosang
`(cid:17)(cid:41)(cid:45)(cid:28)(cid:43)(cid:92) (cid:38)(cid:82)(cid:80)(cid:80)(cid:76)(cid:86)(cid:86)(cid:76)(cid:82)(cid:81) (cid:17)(cid:46)(cid:39)(cid:29)(cid:32)(cid:43)(cid:7)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:3)
`132674998
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:9)(cid:41)(cid:39)(cid:39)(cid:36)(cid:44)(cid:44)(cid:36)(cid:41)(cid:40) (cid:11)(cid:49)(cid:42)(cid:36)(cid:43)(cid:32)(cid:44)(cid:7)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`09/14/2024
`(cid:49)(cid:82)(cid:87)(cid:68)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:79)(cid:76)(cid:81)(cid:72)(cid:3)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:82)(cid:16)(cid:89)(cid:76)(cid:71)(cid:72)(cid:82)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:88)(cid:81)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)
`
`(cid:39)(cid:40)(cid:54)(cid:38)(cid:53)(cid:44)(cid:51)(cid:55)(cid:44)(cid:50)(cid:49)(cid:3)(cid:50)(cid:41)(cid:3)(cid:36)(cid:55)(cid:55)(cid:36)(cid:38)(cid:43)(cid:40)(cid:39)(cid:3)(cid:39)(cid:50)(cid:38)(cid:56)(cid:48)(cid:40)(cid:49)(cid:55)
`
`(cid:55)(cid:76)(cid:87)(cid:79)(cid:72)(cid:3)(cid:82)(cid:85)(cid:3)(cid:55)(cid:92)(cid:83)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:29) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`Affidavit
`
`(cid:39)(cid:82)(cid:70)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:39)(cid:68)(cid:87)(cid:72)(cid:29) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`04/01/2022
`
`(cid:49)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:51)(cid:68)(cid:74)(cid:72)(cid:86)(cid:3)(cid:11)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:81)(cid:82)(cid:87)(cid:68)(cid:85)(cid:76)(cid:68)(cid:79)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:87)(cid:72)(cid:12)(cid:29) (cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)(cid:66)
`7
`
`Apotex v. Cellgene - IPR2023-00512
`Petitioner Apotex Exhibit 1010-0007
`
`